Scott Harris has served as Chief Medical Officer of Altimmune since 2019. He has 20 years of experience of development in gastroenterology, hepatology and metabolism therapeutics. He co-founded Lyric Pharmaceuticals in 2015, where he raised a $20.8 M Series A financing round and served as its Chief Medical Officer. Dr. Harris also served as Chief Medical Officer of Avaxia Biologics and Ocera Therapeutics, and he headed clinical development at Napo Pharmaceuticals, where he authored the ADVENT study, the first Phase 2/3 adaptive trial to result in a drug approval (Mytesi®, 2012). Dr. Harris has an MD from Harvard Medical School. He completed medical residencies at John Hopkins Hospital and the University of Pennsylvania and a Gastroenterology and Hepatology Fellowship at Yale University School of Medicine. He serves on the scientific advisory board of Protagonist Therapeutics and RedHill Biopharmaceuticals and holds a seat on the faculty of Georgetown University School of Medicine, where he teaches a graduate course in drug development.